EndoSpan

Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Endospan helps make the treatment of aneurysms, dissections, and aortic lesions simpler and less invasive, making it a suitable choice for patients with limited treatment options. Endospan's HORIZON system can be used in a single-sided approach, generally shortening and simplifying EVAR procedures. It is especially useful for patients for whom a two-sided approach is physically impossible because of occlusions, natural anatomical contraindications, or other pathologies arising from prior surgical intervention. The company's NEXUS is an aortic stent graft system whose modular approach offers a minimally invasive endovascular solution for patients diagnosed with an aneurysm in the ascending aorta or the aortic arch. In March 2019, Endospan announced that it received the CE Mark for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.

EndoSpan has raised $20M in total funding across 5 rounds. The company is currently at the B stage. Key investors include Artivion, CryoLife, Xizang Haisco Pharmaceutical Group.

EndoSpan was founded in 2008 by Alon Shalev (Founder), Rafi Benary (Co-Founder).

EndoSpan operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

EndoSpan is based in Maskit Street 4, Herzliyya, Israel, Center District.